טוען...
The TAT-RasGAP(317-326) anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner
Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase...
שמור ב:
| הוצא לאור ב: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Impact Journals LLC
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5325447/ https://ncbi.nlm.nih.gov/pubmed/27602963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11841 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|